Replies to post #13821 on Biotech Values

[randychub]

gtcb - "Perhaps moving forwards depends on the successful approval of ATryn."

I was thinking the same thing, but why not just wait until approval if that was the case.

I really like the fact that the deal is for a Mab.

"the value offered by transgenic technology for the production of antibody products such as SC101," noted Gregory Liposky

" a very large scale product at significantly lower capital investment."

GTCB stock holders will be very happy if this becomes common place for Mab dependent bio's.

Randy


P.S. I sold my IMCL today and plan on buying amln back.